Extended Data Fig. 7: The combination of lenvatinib and gefitinib suppresses tumour growth without toxicity in cell-line-derived immunodeficient mouse models in vivo.
From: EGFR activation limits the response of liver cancer to lenvatinib
a–j, Liver cancer cells were grown as tumour xenografts in BALB/c nude mice. After tumour establishment (~200 mm3), mice were treated with vehicle, lenvatinib (4 mg kg−1), gefitinib (80 mg kg−1) or lenvatinib (4 mg kg−1) plus gefitinib (80 mg kg−1), for the indicated number of days. Representative images of H&E, PCNA, Ki-67, cleaved caspase-3 and CD31 staining in SNU449 (a) and Huh6 (b) xenograft models. Scale bars, 50 μm. c–j, Quantification of PCNA+ cells (c, g), Ki-67+ cells (d, h), cleaved caspase-3+ cells (e, i) and microvessel density (MVD) (f, j) per high-power field in representative sections from each group. n = 6 per group. Data are mean ± s.e.m. P values were determined by two-sided unpaired Student’s t-test. k, l, The body weight of mice in the SNU449 (k) and Huh6 (l) xenograft models. Data are mean ± s.e.m. n = 6 mice per group
